** WuXi XDC Cayman 2268.HK rises 4.4% to HK$30.75; set for a second straight session of gains
** Chinese antibody drug developer sees 2024 rev, net profit and adjusted net profit jumping more than 85%, 260% and 170% y/y, respectively, on demand from antibody drug conjugate and bioconjugate industries
** Profit margin improving on high utilisation rate of co's production facilities; faster ramp-up of production lines also increases operating efficiency
** Stock third biggest pct gainer on Hong Kong's healthcare index .HSCIH, which is down 0.7%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。